🔗 Share this article

As America undertakes sweeping changes to its immunization recommendations, an unexpected name has surfaced unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by expressing skepticism about coronavirus vaccinations during the global health crisis and has focused upon possible fatalities after COVID-19 vaccination in her brief time at the FDA.

Planned Shifts to Pediatric Vaccine Schedule

Public health authorities planned to unveil radical revisions to the pediatric immunization program in December, aligning the US with Denmark’s vaccine program, it is understood – a major change that would put the US out of step with a large portion of the global community with no evidence for public health gain. The planned update has been pushed back until the coming year.

Instead of the director of the vaccine center, Høeg is set to present at the event. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the center this calendar year.

Consolidating Power at the FDA

The acting appointment might represent a closer partnership between the drug and biologics divisions as Høeg and Dr. Prasad consolidate power at the FDA – and it points to a greater focus upon dismantling long-standing vaccines at the FDA.

Dr. Høeg has repeatedly called for ending certain childhood vaccine recommendations in the US to become more in line with the Danish model, a society with universal health coverage and a number of inhabitants roughly the size of Wisconsin’s.

So far public appearances, she has continued to focus on vaccination policy – typically the responsibility of Prasad, director of the FDA’s CBER – instead of drug regulation.

Questions Over Expertise

Dr. Høeg has no obvious track record in pharmaceutical research, regulation or administrative roles, which has been standard for former leaders of the biologics center. She has served at the FDA as a senior adviser to the agency head and the vaccine center since spring.

“It seems she lacks to have the requisite experience” for leading the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in running a large organization. She is not an expert in drug approvals.”

Past directors of the center would “grasp laws and regulations and the research of pharmaceutical innovation”, noted Janet Woodcock. “Frankly, she lacks the sort of resume that prior appointees who ran the center have had.”

This division has an vast range of responsibilities at the agency, Woodcock emphasized.

“Many people just pays attention on the new drug program, but the generic program approves numerous generic medications. There’s a biosimilars division, non-prescription drug unit and other areas, and every single one must be looked after,” she noted. “The area you overlook, that is the part that I always told people is going to bite you.”

There is also, a significant management element to the role, which oversees more than 5,000 employees. “It is a huge leadership role, if you do it right,” Woodcock concluded.

Agency Reaction and Controversial Initiatives

In response to questions about Høeg’s fitness for the role and whether this appointment represents increased cooperation among agency officials on vaccines, a representative said that the “inquiries rely on incorrect premises”.

“This background aligns with the functions of her job,” the spokesperson stated, pointing to the period Dr. Høeg spent counseling the agency head on “drug safety and approval science, including computational safety modeling and vaccine surveillance”.

In her interim role, Høeg assumes responsibility for the agency head's new priority voucher program, a contentious one-day therapy clearance system that allegedly worried her former heads. “How are these therapies being picked for this fast-track system? Who is making the calls?” Dr. Howard questioned. “There is a lot of secrecy occurring at the agency right now.”

In general, he stated, “the Food and Drug Administration looks to be trending towards more relaxed rules of all drugs, aside from shots.”

Documented History on Immunizations

Regarding vaccines, Dr. Høeg has a clearer, if troubling, track record, Howard said. She published a study using unverified public submissions to assess the frequency of myocarditis after COVID-19 vaccination. She counseled the state of Florida chief medical officer Joseph Ladapo, who allegedly have altered data to indicate Covid vaccinations are riskier than they are.

Part of her “wish list” for the new federal leadership featured altering regulations for novel immunizations and ending “unnecessary” immunizations, she remarked following the vote on a audio program. At the FDA, Høeg has according to sources floated the idea of excluding teenage boys from getting COVID-19 vaccinations.

“She is an all-around ideologue who begins with her beliefs and tailors the evidence to retrofit the science in a extremely misleading, untruthful fashion,” Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg became part of other contrarians, {like|